Your browser doesn't support javascript.
loading
In-depth characterisation of a cohort of individuals with missense and loss-of-function variants disrupting FOXP2.
Morison, Lottie D; Meffert, Elisabeth; Stampfer, Miriam; Steiner-Wilke, Irene; Vollmer, Brigitte; Schulze, Katrin; Briggs, Tracy; Braden, Ruth; Vogel, Adam; Thompson-Lake, Daisy; Patel, Chirag; Blair, Edward; Goel, Himanshu; Turner, Samantha; Moog, Ute; Riess, Angelika; Liegeois, Frederique; Koolen, David A; Amor, David J; Kleefstra, Tjitske; Fisher, Simon E; Zweier, Christiane; Morgan, Angela T.
Afiliação
  • Morison LD; Speech and Language, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Meffert E; SRH University of Applied Health Sciences, Gera, Germany.
  • Stampfer M; Medical Genetics Center, Munich, Germany.
  • Steiner-Wilke I; Centre for Cleft Palate & Craniofacial Malformations, Tuebingen University Hospital, Tubingen, Germany.
  • Vollmer B; Department of Paediatric Neurology and Developmental Medicine, University Children's Hospital Tuebingen, Tuebingen, Germany.
  • Schulze K; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Briggs T; Paediatric Neurology, Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Braden R; Department of Psychology, Heidelberg University, Heidelberg, Germany.
  • Vogel A; Division of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, School of Biological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
  • Thompson-Lake D; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
  • Patel C; Speech and Language, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Blair E; Centre for Neuroscience of Speech, University of Melbourne, Melbourne, Victoria, Australia.
  • Goel H; Redenlab Pty Ltd, Melbourne, Victoria, Australia.
  • Turner S; Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Moog U; Genetic Health Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
  • Riess A; Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Liegeois F; Hunter Genetics, Waratah, New South Wales, Australia.
  • Koolen DA; Speech and Language, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Amor DJ; School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.
  • Kleefstra T; Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.
  • Fisher SE; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
  • Zweier C; Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Morgan AT; Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.
J Med Genet ; 60(6): 597-607, 2023 06.
Article em En | MEDLINE | ID: mdl-36328423
ABSTRACT

BACKGROUND:

Heterozygous disruptions of FOXP2 were the first identified molecular cause for severe speech disorder childhood apraxia of speech (CAS), and yet few cases have been reported, limiting knowledge of the condition.

METHODS:

Here we phenotyped 28 individuals from 17 families with pathogenic FOXP2-only variants (12 loss-of-function, five missense variants; 14 males; aged 2 to 62 years). Health and development (cognitive, motor, social domains) were examined, including speech and language outcomes with the first cross-linguistic analysis of English and German.

RESULTS:

Speech disorders were prevalent (23/25, 92%) and CAS was most common (22/25, 88%), with similar speech presentations across English and German. Speech was still impaired in adulthood, and some speech sounds (eg, 'th', 'r', 'ch', 'j') were never acquired. Language impairments (21/25, 84%) ranged from mild to severe. Comorbidities included feeding difficulties in infancy (10/26, 38%), fine (13/26, 50%) and gross (13/26, 50%) motor impairment, anxiety (5/27, 19%), depression (6/27, 22%) and sleep disturbance (10/24, 42%). Physical features were common (22/27, 81%) but with no consistent pattern. Cognition ranged from average to mildly impaired and was incongruent with language ability; for example, seven participants with severe language disorder had average non-verbal cognition.

CONCLUSIONS:

Although we identify an increased prevalence of conditions like anxiety, depression and sleep disturbance, we confirm that the consequences of FOXP2 dysfunction remain relatively specific to speech disorder, as compared with other recently identified monogenic conditions associated with CAS. Thus, our findings reinforce that FOXP2 provides a valuable entry point for examining the neurobiological bases of speech disorder.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apraxias / Transtornos da Linguagem Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Child / Humans / Male Idioma: En Revista: J Med Genet Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Apraxias / Transtornos da Linguagem Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Child / Humans / Male Idioma: En Revista: J Med Genet Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália